RxDoctor Payments Data

Andrej Petrov, MD

Allergy/ Immunology · Pittsburgh, PANPI 1538134069

Payments from drug & device makers

$79,803in general payments, 2019–2025

Across 186 payments — averaging $429.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$32K
  • Genentech USA, Inc.$10K
  • GSK$8K
  • Blueprint Medicines Corporation$8K
  • CSL Behring$7K
  • Roche Products Limited$6K
  • plus $9K from 12 others

What the payments were for

  • Consulting fees$47,66665%
  • Speaking & faculty fees$11,07615%
  • Travel & lodging$5,3867%
  • Food & beverage$9,50813%
  • Education$800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy/ immunology providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$30,683
Medicare patients
155
Services billed
771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5025$229,133
Dupixent SyringeDupilumab56$218,822
XolairOmalizumab72$151,093
Fasenra PenBenralizumab23$129,578
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$95,795
NucalaMepolizumab25$93,279
Dupixent PenDupilumab18$64,692
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$44,570
Breo ElliptaFluticasone/Vilanterol90$40,295
Epinephrine55$13,745
Fluticasone-SalmeterolFluticasone Propion/Salmeterol79$12,800
Fluticasone Propionate HfaFluticasone Propionate50$12,043
Spiriva RespimatTiotropium Bromide17$8,346
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate35$8,327
Arnuity ElliptaFluticasone Furoate30$7,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$7,358$229,13325 claims
GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta$8,005$185,949212 claims
Grifols USA, LLCGamunex-C$431$95,79513 claims
AstraZenecaSymbicort$1,073$5,35421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.

Other allergy/ immunology in Pittsburgh

Where these figures come from

Is this you, or does something look wrong? →